Pavel Kapysh/Shutterstock
The story of BrainStorm Cell Therapeutics NurOwn is a portrait of the inherent challenges in developing an effective treatment for one of humanitys most elusive diseases, amyotrophic lateral sclerosis (ALS). It is also a cautionary tale for other therapeutic hopefuls in the space.
NurOwn is a platform comprised of autologous mesenchymal stem cells (MSCs) and neurotrophic factors (NTFs). The MSC-NTF cells are used to deliver multiple NTFs as well as immunomodulatory cytokines to sites of damage, producing a biological effect that may slow or stabilize the progression of diseases such as ALS and multiple sclerosis (MS). The approach borrows its inspiration from the field of oncology.
Were standing on the shoulders of giants because were following a very successful set of products that have been made for cancer. The success of the CAR-T world has really created an opportunity for us to use the same model to create cellular therapy for patients, said BrainStorm president and chief medical officer, Dr. Ralph Kern.
In February, the U.S. Food and Drug Administration (FDA) found that high-level data from the phase III trial of NurOwn in ALS was not sufficient to support a Biologics License Application (BLA).
While the trial hit the primary treatment response endpoint, with 34.7% achieving an improvement of 1.5 points per month, the placebo response of 27.7% exceeded those of others observed in contemporary ALS trials.
When looking only at a pre-specified subgroup of patients with early-stage disease based on an ALS Functional Rating Scale - Revised (ALSFRS-R) baseline score of 35, however, NurOwn shined, demonstrating a meaningful response across all primary and secondary endpoints. In this cohort, 34.6% of NurOwn recipients received a clinically significant response versus only 15.6% in the placebo group.
Outcry from the ALS community was swift.
When trial participant, Phil Green, began treatment with NurOwn in May 2019, his ALSFRS score was 33, where it remained through three stem cell transplants until March 2020, seven months following the last treatment. A little more than a year later, Greens score has fallen swiftly to 27.
What if I would have continued with NurOwn? Would I still be at 33 today? The difference in those six points is me being able to get up and downstairs and walk without any assistance. I have not been upstairs in my house in almost a year, Green said.
Green told BioSpace that he was very disappointed in the FDAs request for more data to prove NurOwns benefit.
The data showed that a subgroup of trial participants had a significant treatment effect. We really need to take a different approach in ALS to evaluate therapeutic efficacy. ALS is a terminal disease with no FDA-approved disease-modifying treatments. If a therapy shows that it helps some people with ALS, that is a huge win for our disease, he said. In the case of NurOwn, it seemed to be most effective in people that were earlier in their disease progression with an ALSFRS-R of 35 or more. Who has an ALSFRS-R higher than 35? Nearly everyone that just received a diagnosis of ALS!
The study also highlighted the question of biomarkers in ALS research, as NurOwn was found to significantly increase neurotrophic factors and cause a reduction in both neuroinflammatory and neurodegenerative biomarkers.
While the value of biomarkers is well established in oncology, the relationship between clinical and biological evidence in the neurodegenerative disease space is still in its infancy.
We showed really quite impressive changes in various biomarkers, and we equally saw some very exciting changes in the clinical endpoints. But right now, that relationship to the point where you would have an approval has not been established in ALS, or really in any neurodegenerative disease, said BrainStorm EVP and Head of Global Clinical Research, Stacy Lindborg, Ph.D.
There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve. Implicit in the R is the reality that science still does not have a complete understanding of the disease pattern behind ALS.
The NurOwn trial may have exposed the limitations near the bottom of the scale. While BrainStorm had anticipated a baseline number of around 35 on the scale, it ended up with one around 30.
Depending on which patients participate in a trial, one can be more affected by it or less affected. I think its safe to say that we enrolled a group of ALS patients in our trial that were more advanced than traditional ALS clinical trials. As a consequence, I think we saw the limitations of the scale a little bit more than other trials in terms of the rate of progression, said Kern.
Clene Nanomedicine, Inc., which is developing a nanotherapeutic, CNM-Au8, aimed at reversing neurodegeneration by enhancing naturally occurring cellular metabolism, took this complexity to heart when designing its ALS trials.
Were not that concerned about the ALSFRS scale. In fact, thats one of the reasons why we wanted to do a mix of endpoints. We maybe took a little bit of learning from BrainStorms experience on the design of our own studies. Were looking at collectively at MUNIX, which is not usually done in this country because its not reimbursed, but it is done ex-US, said Clene president and CEO, Rob Etherington.
Clene is simultaneously investigating CNM-Au8 in an Australian RESCUE Phase II study, and the Phase III Healey ALS Platform Trial. The primary endpoint in the RESCUE trial is the Motor Unit Number Index (MUNIX), while the Healey trial counts ALSFRS-R as its primary measurement. Vital capacity is a secondary endpoint in both studies.
So these two studies kind of dovetail together, and the data in Clenes case is going to emerge from both of them within a matter of months. Taken together, it will be very exciting to see if we can improve neurological function with the oral administration of a nanocatalyst such as our CNM-Au8, said Etherington.
If BrainStorm chooses to take another stab at applying for a BLA based on the pre-specified cohort, precedent could be on the companys side.
RADICAVA (edaravone), developed by Mitsubishi Tanabe, was approved by the FDA on May 5, 2017, becoming the first new ALS treatment to be approved in 22 years. But Radicavas path to the market was anything but straightforward.
[ALS] is heterogeneous, and sometimes its really important, even when a drug doesnt work in everybody, to look at if theres a subset that might have benefited. Id say we learned that lesson from a different drug, a marketed drug now for ALS called Radicava where the first trial was also negative in everybody, but a subset of people responded. Those were early fast progressors, and when they repeated the studies just in that group, it was positive and that led to marketing. So it is really important to look at all the data, and especially for a fatal illness like ALS, to make sure youre not missing a group that might have responded said Dr. Merit Cudkowicz, director of the Healey & AMG Center for ALS who was also an investigator on the NurOwn trial.
NurOwn recently scored a win in another neurodegenerative disease, displaying promising topline results in a phase II study assessing neurologic function, cognition and biomarkers. BrainStorm has not yet announced a phase III trial.
Similar to our ALS data, were currently reviewing it with MS experts and the leadership of the advocacy community. We want to get their feedback and reflection on our data first, said Kern. During that process, well obviously have a better feel for the data. Well know what feels right and what is right. Itll come to us soon.
Read the original post:
NurOwn: A Study in the Complexity of ALS Trials - BioSpace
- Storage conditions affect the composition of the lyophilized secretome of multipotent mesenchymal stromal cells ... - Nature.com - May 4th, 2024
- Mesenchymal Stem Cells Market Will Increase USD 10 Billion By 2033 - PharmiWeb.com - May 4th, 2024
- Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies | Eye - Nature.com - April 10th, 2024
- Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics - StreetInsider.com - April 10th, 2024
- Adipose Derived Stem Cell Therapy Market Will Show the Highest Growth Rates, Incredible Demand by 2031 - WhaTech - April 3rd, 2024
- Injectable microspheres adhering to the cartilage matrix promote rapid reconstruction of partial-thickness cartilage defects - ScienceDirect.com - March 30th, 2024
- Safety and Potential Effect of Intrauterine Infusion of Autologous Adipose Tissue-Derived Regenerative Cells in ... - Cureus - March 30th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- Clinical application of mesenchymal stem cell in regenerative medicine ... - March 22nd, 2024
- Mesenchymal Stem Cells: The Past Present and Future - March 22nd, 2024
- CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General ... - Yahoo Finance - March 20th, 2024
- Overexpression of Wnt5a promoted the protective effect of mesenchymal stem cells on Lipopolysaccharide-induced ... - BMC Infectious Diseases - March 20th, 2024
- Mesenchymal Stem Cells: What We Have Learned and How to Manage Them - MDPI - March 17th, 2024
- Mesenchymal stem cells and their microenvironment - March 17th, 2024
- Mesenchymal stem/stromal cells as a valuable source for the treatment ... - March 17th, 2024
- Proteomic characterization of hUC-MSC extracellular vesicles and evaluation of its therapeutic potential to treat ... - Nature.com - March 13th, 2024
- The impact understanding of exosome therapy in COVID-19 and preparations for the future approaches in dealing with ... - Nature.com - March 13th, 2024
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance UK - March 7th, 2024
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance - March 6th, 2024
- Combatting osteoarthritis with cartilage replacement therapy - Drug Target Review - March 3rd, 2024
- Ethical considerations in Stem Cell therapy for ALS - Cyprus Mail - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- Stem Cell Therapy for Ulcerative Colitis - Health Central - February 27th, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 24th, 2024
- Early differentiation of mesenchymal stem cells is reflected in their dielectrophoretic behavior | Scientific Reports - Nature.com - February 22nd, 2024
- Orthopaedics Department's Regenerative Research Highlighted at ORS Annual Meeting - InventUM - University of Miami - February 20th, 2024
- Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona ... - Nature.com - February 18th, 2024
- New University spin-out developing novel adult stem cell-based Therapies - News - University of Liverpool - News - February 15th, 2024
- Examining the potential of the common bovine as a potential therapeutic research model - Medical Xpress - February 15th, 2024
- Intentional Interference: Genetic Engineering Medium Aids The Transfection Of MSCs With siRNA - BioProcess Online - February 15th, 2024
- Cellular senescence is associated with osteonecrosis of the femoral head while mesenchymal stem cell conditioned ... - Nature.com - February 9th, 2024
- Stem Cell Therapy for Crohns Disease Shows Promising Results - RegMedNet - February 9th, 2024
- Targeted transcriptomic analysis of synovial tissues from horses with septic arthritis treated with immune-activated ... - American Veterinary Medical... - February 7th, 2024
- Mesenchymal Stem Cell Immunomodulation: Mechanisms and ... - Cell Press - February 7th, 2024
- New Cell Therapy for ARDS: A Groundbreaking Development and Other Respiratory Health Breakthroughs - Medriva - February 7th, 2024
- Effective treatment of optic neuropathies by intraocular delivery of MSC-sEVs through augmenting the G-CSF ... - pnas.org - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 29th, 2024
- Out-of-this-world study will test how stem cells function in space - YP - January 29th, 2024
- The Applications of Cell Therapy - Technology Networks - January 26th, 2024
- STEM CELL THERAPY FOR MS COST: WHAT YOU NEED TO KNOW? - Island Echo - January 24th, 2024
- Understanding Neuromyelitis Optica: Role of NF-B and Therapeutic Potential - Medriva - January 20th, 2024
- Faculty member Arnold Caplan passes away The Daily The Daily - The Daily | Case Western Reserve University - January 18th, 2024
- Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ... - Nature.com - January 11th, 2024
- Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs ... - Journal of Translational... - January 11th, 2024
- NurOwn and its exosomes for ALS given patents in Europe, elsewhere - ALS News Today - January 8th, 2024
- Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian ... - Nature.com - January 8th, 2024
- First in Class Combination Stem Cell and Exosome Therapy to Treat Pulmonary Fibrosis in Long Haul Covid Patients ... - Yahoo Finance - January 4th, 2024
- Choosing the Right Excipients for MSC and iPSC Therapies - Pharmaceutical Technology Magazine - January 4th, 2024
- Mitochondria Transplantation Therapy It's Farther Along Than You Think - BioProcess Online - January 2nd, 2024
- Embryonic-stem-cell-derived mesenchymal stem cells relieve experimental contact urticaria by regulating the functions ... - Nature.com - December 21st, 2023
- Type I collagen and fibromodulin enhance the tenogenic phenotype of hASCs and their potential for tendon ... - Nature.com - December 19th, 2023
- Could the 'central dogma' of biology be misleading bioengineers? - Phys.org - December 13th, 2023
- The Risks of Stem Cell and Exosome Treatments for Long COVID: A Call for Stricter Regulations - Medriva - December 13th, 2023
- Mesenchymal stem cells from biology to therapy - PMC - December 11th, 2023
- The Safety and Efficacy of Human Umbilical Cord-Derived ... - Cureus - December 5th, 2023
- The pivotal role of Nrf2 signal axis in IDD | JIR - Dove Medical Press - December 5th, 2023
- Futuristic Novel Therapeutic Approaches in the Treatment of ... - Cureus - December 3rd, 2023
- Cartilage's Contribution in Otology: A Comprehensive Review of Its ... - Cureus - December 3rd, 2023
- Mesenchymal stem or stromal cells: a review of clinical applications ... - November 29th, 2023
- Comparative evaluation of 3D-printed and conventional implants in ... - Nature.com - November 29th, 2023
- Expression of E-cadherin and N-cadherin in Epithelial-to ... - Cureus - November 29th, 2023
- Enhancing the immunosuppressive properties of human umbilical cord mesenchymal stem cells - Phys.org - November 29th, 2023
- 'Great Potential' in Stem Cell Therapies for Knee Osteoarthritis ... - Pain News Network - November 25th, 2023
- Dietary Sources, Bioavailability, and Functions of Ascorbic Acid ... - Cureus - November 25th, 2023
- FY 2024 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- Real-world data suggest effectiveness of the allogeneic ... - Journal of Translational Medicine - November 23rd, 2023
- Mesenchymal Stem Cells: Characteristics, Function, and Application - November 23rd, 2023
- Combined application of therapeutic viruses and nanomaterials to ... - News-Medical.Net - November 23rd, 2023
- Progress in the Development of Stem Cell-Derived Cell-Free ... - Dove Medical Press - November 23rd, 2023
- Improving the therapeutic efficacy of oncolytic viruses for cancer ... - Journal of Translational Medicine - November 23rd, 2023
- 11.22.23 -- How To Lose A Batch In 10 Days - BioProcess Online - November 23rd, 2023
- The Pros and Cons of Mesenchymal Stem Cell-Based Therapies - November 19th, 2023
- Leptin's influence on MMP-1 expression | JIR - Dove Medical Press - November 15th, 2023
- TWIST1 and TSG6 are coordinately regulated and function as ... - Science - November 11th, 2023
- Association between severe acute malnutrition in childhood and ... - BioMed Central - November 11th, 2023
- Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders - Yahoo Finance - November 11th, 2023
- Stem Cell Restore Reviews - Does It Work? Real Green Valley ... - The Daily World - November 11th, 2023
- Biological and genetic characterization of a newly established ... - Nature.com - November 11th, 2023
- Placental Stem Cell Collection and Storage Industry Scope ... - Argyle Report - November 9th, 2023
- In Vitro Evaluation of Light-Induced Cytotoxic Property: Synergistic ... - Cureus - November 9th, 2023
Recent Comments